Terry Evans

606 total citations
24 papers, 420 citations indexed

About

Terry Evans is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Terry Evans has authored 24 papers receiving a total of 420 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 6 papers in Pathology and Forensic Medicine. Recurrent topics in Terry Evans's work include Lung Cancer Treatments and Mutations (13 papers), Colorectal Cancer Treatments and Studies (10 papers) and Lymphoma Diagnosis and Treatment (6 papers). Terry Evans is often cited by papers focused on Lung Cancer Treatments and Mutations (13 papers), Colorectal Cancer Treatments and Studies (10 papers) and Lymphoma Diagnosis and Treatment (6 papers). Terry Evans collaborates with scholars based in United States, United Kingdom and Australia. Terry Evans's co-authors include Ramesh K. Ramanathan, Samuel A. Jacobs, Michael K. Wong, Edward J. Wing, Chandra P. Belani, Judith M. Joyce, Jennifer L. Osborn, Christine M. Walko, Roger Day and Helen X. Chen and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Terry Evans

24 papers receiving 412 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Terry Evans United States	11	302	171	110	73	65	24	420
Zhaohui Chu China	13	263 0.9×	183 1.1×	57 0.5×	31 0.4×	161 2.5×	36	454
Apurvasena Parikh United States	10	235 0.8×	187 1.1×	51 0.5×	95 1.3×	94 1.4×	37	409
Dominique Cazals France	9	247 0.8×	68 0.4×	143 1.3×	82 1.1×	138 2.1×	11	525
Antonio Cubillo Gracián Spain	15	439 1.5×	136 0.8×	119 1.1×	55 0.8×	108 1.7×	30	697
Boyd Mudenda United States	10	270 0.9×	86 0.5×	25 0.2×	89 1.2×	98 1.5×	20	435
Robert Alter United States	10	264 0.9×	206 1.2×	46 0.4×	27 0.4×	132 2.0×	29	466
Macdonald Js United States	10	248 0.8×	120 0.7×	67 0.6×	20 0.3×	80 1.2×	20	436
Gabriel Prolla Brazil	8	196 0.6×	43 0.3×	158 1.4×	30 0.4×	97 1.5×	17	427
Aline Charabaty United States	12	358 1.2×	170 1.0×	88 0.8×	21 0.3×	78 1.2×	27	575
Joshua E. Reuss United States	13	370 1.2×	257 1.5×	30 0.3×	35 0.5×	124 1.9×	54	521

Countries citing papers authored by Terry Evans

Since Specialization

Citations

This map shows the geographic impact of Terry Evans's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Terry Evans with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Terry Evans more than expected).

Fields of papers citing papers by Terry Evans

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Terry Evans. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Terry Evans. The network helps show where Terry Evans may publish in the future.

Co-authorship network of co-authors of Terry Evans

This figure shows the co-authorship network connecting the top 25 collaborators of Terry Evans. A scholar is included among the top collaborators of Terry Evans based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Terry Evans. Terry Evans is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wang, Hong, Terry Evans, James G. Herman, et al.. (2024). Brief Report: Phase II Clinical Trial of Atezolizumab in Advanced Nonsmall Cell Lung Cancer Patients Previously Treated With PD-1-Directed Therapy. Clinical Lung Cancer. 26(1). 78–81. 1 indexed citations

Wang, X., Erin M. Bertino, Scott Antonia, et al.. (2023). A single-arm, multicenter, phase II trial of osimertinib in patients with epidermal growth factor receptor exon 18 G719X, exon 20 S768I, or exon 21 L861Q mutations. ESMO Open. 8(2). 101183–101183. 12 indexed citations

Ganz, Patricia A., Ron D. Hays, Karen L. Spritzer, et al.. (2022). Health‐related quality of life outcomes after neoadjuvant chemoradiotherapy for rectal cancer in NRG Oncology/NSABP R‐04. Cancer. 128(17). 3233–3242. 6 indexed citations

Blackhall, Fiona, Terry Evans, Ji‐Youn Han, et al.. (2012). Impact of Crizotinib Treatment on Patient-Reported Symptoms and Quality of Life (QOL) in Advanced Alk-Positive Non-Small Cell Lung Cancer (NSCLC). Annals of Oncology. 23. ix403–ix403. 6 indexed citations

Pennell, Nathan A., Joel W. Neal, Ramaswamy Govindan, et al.. (2011). The SELECT trial: A multicenter phase II trial of adjuvant erlotinib (E) in patients with resected, early-stage non-small cell lung cancer (NSCLC) and confirmed mutations in the epidermal growth factor receptor (EGFR).. Journal of Clinical Oncology. 29(15_suppl). TPS209–TPS209. 5 indexed citations

Ramalingam, Suresh S., et al.. (2010). Phase 2 study of irinotecan and paclitaxel in patients with recurrent or refractory small cell lung cancer. Cancer. 116(5). 1344–1349. 14 indexed citations

Brell, Joanna M., Khalid Matin, Terry Evans, et al.. (2009). Phase II Study of Docetaxel and Gefitinib as Second-Line Therapy in Gemcitabine Pretreated Patients with Advanced Pancreatic Cancer. Oncology. 76(4). 270–274. 29 indexed citations

Appleman, Leonard J., Terry Evans, Primo N. Lara, et al.. (2009). Docetaxel and imatinib every 21 days for castration resistant prostate cancer: A phase II trial. Journal of Clinical Oncology. 27(15_suppl). e16086–e16086. 1 indexed citations

Ramalingam, Suresh S., et al.. (2008). Dual Inhibition of the Epidermal Growth Factor Receptor with Cetuximab, an IgG1 Monoclonal Antibody, and Gefitinib, A Tyrosine Kinase Inhibitor, in Patients with Refractory Non-small Cell Lung Cancer (NSCLC): A Phase I Study. Journal of Thoracic Oncology. 3(3). 258–264. 43 indexed citations

10.

Jankowitz, Rachel C., Kenneth A. Foon, The Minh Luong, et al.. (2008). Phase II Study of Short Course CHOP-Rituximab Followed by 90-Y Ibritumomab Tiuxetan as First-Line Treatment for Follicular Lymphoma: An Update and Extension of Preliminary Findings on Predictors of Relapse.. Blood. 112(11). 2001–2001. 1 indexed citations

11.

Jacobs, Samuel A., Steven H. Swerdlow, Jeffrey A. Kant, et al.. (2008). Phase II Trial of Short-Course CHOP-R Followed by 90Y-ibritumomab Tiuxetan and Extended Rituximab in Previously Untreated Follicular Lymphoma. Clinical Cancer Research. 14(21). 7088–7094. 67 indexed citations

12.

Sequist, Lecia V., Renato Martins, David R. Spigel, et al.. (2007). iTARGET: A phase II trial to assess the response to gefitinib in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) tumors. Journal of Clinical Oncology. 25(18_suppl). 7504–7504. 21 indexed citations

13.

Jankowitz, Rachel C., Jennifer L. Osborn, Terry Evans, et al.. (2007). Phase II study of short course CHOP-rituximab (R) followed by ibritumomab tiuxetan (IT) as first-line treatment for follicular lymphoma (FL). Journal of Clinical Oncology. 25(18_suppl). 8005–8005. 6 indexed citations

14.

Appleman, Leonard J., David Friedland, William E. Gooding, et al.. (2007). Phase II trial of oral imatinib in combination with every-three-week intravenous docetaxel in patients with metastatic, hormone- refractory prostate cancer. Journal of Clinical Oncology. 25(18_suppl). 15603–15603. 1 indexed citations

15.

Wu, Michael, Jennifer L. Osborn, Terry Evans, et al.. (2006). Imaging results after CHOP-rituximab followed by ⁹⁰Y ibritumomab tiuxetan and rituximab (R) in patients with previously-untreated follicular lymphoma (FL). Journal of Clinical Oncology. 24(18_suppl). 7589–7589. 2 indexed citations

16.

Wu, Michael, Jennifer L. Osborn, Terry Evans, et al.. (2005). Phase II Trial of Abbreviated CHOP-Rituximab Followed by 90Y Ibritumomab Tiuxetan (Zevalin) and Rituximab in Patients with Previously-Untreated Follicular Non-Hodgkin Lymphoma (NHL).. Blood. 106(11). 2449–2449. 11 indexed citations

17.

Matin, Khalid, Samuel A. Jacobs, Thomas J. Richards, et al.. (2005). A Phase I/II Study of Trimetrexate and Capecitabine in Patients With Advanced Refractory Colorectal Cancer. American Journal of Clinical Oncology. 28(5). 439–444. 4 indexed citations

18.

Ramanathan, Ramesh K., Jimmy J. Hwang, William C. Zamboni, et al.. (2004). Low Overexpression of HER-2/Neu in Advanced Colorectal Cancer Limits the Usefulness of Trastuzumab (Herceptin®) and Irinotecan as Therapy. A Phase II Trial. Cancer Investigation. 22(6). 858–865. 118 indexed citations

19.

Evans, Terry, Alan Winkelstein, Zella R. Zeigler, Richard K. Shadduck, & Kenneth F. Mangan. (1984). Thrombotic thrombocytopenic purpura: Clinical course and response to therapy in eight patients. American Journal of Hematology. 17(4). 401–407. 12 indexed citations

20.

Evans, Terry, et al.. (1984). Failure of erythromycin in treatment of legionella micdadei pneumonia. The American Journal of Medicine. 76(2). 318–320. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact